FDA Approves First Injectable HIV Prevention Drug, Which Beat Out Daily Oral Medication in Tests
Headline from NBC Los Angeles
Apretude’s superior efficacy was apparently driven by the greater ease with which study participants adhered to the every-other-month regimen compared with taking a pill every day.
NBC Los Angeles's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
The US Food and Drug Administration has approved the first injectable medication for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV through sex, it announced Monday.
Apretude’s superior efficacy was apparently driven by the greater ease with which study participants adhered to the every-other-month regimen compared with taking a pill every day.
TUESDAY, Dec. 21, 2021 (HealthDay News) -- The first injection drug to prevent HIV infection was approved by the U.S. Food and Drug Administration on Monday.
The Food and Drug Administration (FDA) has approved the first injectable treatment for HIV pre-exposure prevention (PrEP), providing another option to help individuals at-risk avoid sexually transmitted HIV.
The Food and Drug Administration has approved the first long-acting injectable medication for use as pre-exposure prevention, or PrEP, against HIV, the agency
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
FDA Approves First Injectable HIV Prevention Drug, Which Beat Out Daily Oral Medication in Tests | Since Then
